Full-Time

Patient Navigator

Posted on 9/23/2025

Mirum Pharmaceuticals

Mirum Pharmaceuticals

201-500 employees

ASBT inhibitors for rare liver diseases

No salary listed

San Mateo, CA, USA + 1 more

More locations: Charlotte, NC, USA

Hybrid

Applicants must reside in a location which would allow them to comply with Mirum’s hybrid work policy.

Category
Medical, Clinical & Veterinary (1)
Requirements
  • BA/BS Highly Desired.
  • Registered Nurse (RN), Licensed Practical Nurse (LPN/LVN), Social Worker (BSW), or Case Manager (CCM) preferred.
  • Minimum 5+ years of experience in patient navigation, specialty pharmacy, case management, or patient access preferably in biotech, rare disease, oncology or cell/gene therapy.
  • Strong understanding and experience in working through benefits verification, prior authorization, and reimbursement processes.
  • Exceptional communication, organization, and problem-solving skills that have been demonstrated in producing improved patient experiences and outcomes.
  • Proven ability to work independently in a high-volume, fast paced and patient-focused environment.
  • Empathetic and patient-centered mindset with a commitment to improving rare disease care.
  • Ability to multitask and balance multiple priorities at once.
  • Demonstrated ability to deliver meaningful & concise conversations with integrity and empathy directly to patients and health care providers.
  • Experience using CRM or case tracking systems (Salesforce Health Cloud preferred).
  • In-depth understanding of health insurance benefits, relevant state and federal laws and insurance regulations.
  • Excellent written and oral communication, and problem-solving skills, including the ability to connect with patients, caregivers, and providers.
  • Experience and demonstrated success working in a complex matrix to accomplish goals with a patient centric approach.
  • Strong people skills that demonstrate flexibility, persistence, creativity, empathy, and trust.
  • Robust computer literacy skills including data entry and MS Office-based software programs.
  • Possesses strong business acumen and strategic thinking skills.
  • Ability to identify and handle sensitive issues, working independently and collaboratively within teams.
  • Ability to travel required, ~10%, possibly weekends.
Responsibilities
  • Serve as the main point of contact for patients and caregivers, providing non-clinical guidance and emotional support throughout their treatment journey demonstrating a thorough understanding of the disease state and Mirum product profiles.
  • Provide patients and HCPs a clear understanding of eligibility requirements, program enrollment, reimbursement process, affordability support, and general access for Mirum prescribed therapies.
  • Deliver unparalleled customer service while serving as a brand advocate and program representative; understands the importance of achieving quality outcomes and commit to the appropriate use of resources.
  • Coordinate care between prescribers, specialty pharmacies, and insurance providers to ensure timely drug access and refills.
  • Monitor patient cases to identify potential delays or issues (e.g., prior authorizations, benefit revalidations, prescription renewals) and proactively resolve them.
  • Educate patients and families about program resources, refill schedules, and financial assistance options.
  • Elevate the patient experience by partnering with Mirum’s market access, reimbursement, and specialty pharmacy teams to resolve coverage and dispensing challenges.
  • Support patient onboarding, therapy continuation, and adherence initiatives in alignment with program KPIs.
  • Serve as a resource for patients and healthcare professionals to verify insurance coverage, reimbursement process, and general access for complex pharmaceuticals and ability to understand and explain benefits offered by all payer types including private/commercial and government (i.e., Medicare, Medicaid, VA and DOD).
  • Patient Navigators will be regionally aligned and will serve as an expert on reimbursement, co-pay, foundation assistance, patient assistance program (PAP) issues, and other forms of available support and will be responsible for handling patient and healthcare provider interactions related to these topics in collaboration with the Regional Access Leads and Regional Account Managers.
  • Responsible for communicating insurance benefit investigations, prior authorization and appeal requirements, and triage cases according to program standard operating procedures.
  • Serve as direct point of contact to health care providers for ongoing support and relationship development by acquiring and delivering detailed information regarding a program and/or a patient.
  • Evaluate program enrollment forms for data integrity and missing information.
  • Follow program guidelines and escalate complex cases according to program policy, SOPs, Call Guides, and other program materials.
  • Working in a case management system, documenting status/background in case notes, communicating patient benefits, assisting in the PA/Appeals process and like responsibilities.
  • Act as an assigned liaison to customer contacts (e.g., regional contact for sales representatives), Market Access colleagues, other internal stakeholders and healthcare providers.
  • Works with the Program Supervisor, on a day-to-day basis to maintain open lines of communication and share awareness regarding patient status, prescriber feedback/satisfaction and program effectiveness.
  • Maintains a high level of ethical conduct regarding confidentiality and privacy.
  • Help maintain team morale by consistently demonstrating positive attitude.
  • Maintain accurate, compliant documentation within CRM and case management systems.
  • Conducts miscellaneous tasks or projects as assigned identify and report pharmacovigilance information as required, i.e., Adverse Events, and Product Quality Complaints.
Desired Qualifications
  • Experience in biotech, rare disease, oncology or cell/gene therapy preferred.
Mirum Pharmaceuticals

Mirum Pharmaceuticals

View

Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.

Company Size

201-500

Company Stage

IPO

Headquarters

Foster City, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • LIVMARLI sales hit $360M in 2025, guiding $630-650M in 2026 with 69% YoY growth.
  • Phase 3 EXPAND enrollment complete, topline Q4 2026 supports biliary atresia label expansion.
  • Four pivotal readouts through 2027, including volixibat PSC data Q2 2026 and brelovitug HDV 2H 2026.

What critics are saying

  • EXPAND trial fails primary pruritus endpoint in Q4 2026, blocking LIVMARLI expansion.
  • VISTAS volixibat misses PSC pruritus endpoint Q2 2026, delaying 2026 filing.
  • AZURE-1/4 brelovitug fails virologic response in 2H 2026, writing down Bluejay acquisition.

What makes Mirum Pharmaceuticals unique

  • LIVMARLI is first FDA-approved IBAT inhibitor for ALGS cholestatic pruritus since 2021.
  • Mirum holds worldwide rights to brelovitug, Phase 3 HDV monoclonal antibody with Breakthrough Therapy designation.
  • Pipeline targets unmet needs in PSC, PBC, and biliary atresia via volixibat and LIVMARLI expansions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-3%

2 year growth

0%
Yahoo Finance
Apr 13th, 2026
Mirum Pharmaceuticals could be worth $26B as biotech stock soars 120% with four pivotal drug trials ahead

Mirum Pharmaceuticals has seen its shares surge over 120% in the past year, driven by strong commercial performance and an advancing pipeline. The biotech company markets three approved therapies, with Livmarli leading growth at 69% year-over-year to $360 million in Q4 2025. Net product sales jumped 50% in the quarter, enabling Mirum to achieve positive free cash flow in 2025. The company expects four pivotal clinical readouts over the next 18 months, including Phase 3 data for volixibat in Primary Sclerosing Cholangitis due in Q2 2026. Peak sales estimates for Mirum's pipeline candidates exceed $4 billion. With a current market capitalisation of $5.8 billion, analysts suggest the company could reach approximately $26 billion in value if its therapies achieve their commercial potential.

Yahoo Finance
Apr 1st, 2026
Mirum reports record Q1 2025 revenue of $111.6M, raises full-year guidance to $450M

Mirum Pharmaceuticals reported first-quarter 2025 revenues of $111.6 million, representing 61% year-over-year growth. The company has raised its full-year revenue guidance to $435 million to $450 million, driven by strong performance across its three commercial medicines. Since the start of 2025, Mirum has secured three regulatory approvals: CTEXLI for CTX treatment in February, LIVMARLI's approval in Japan for PFIC and Alagille syndrome through partner Takeda, and a single-tablet formulation of LIVMARLI from the FDA. The company's VISTAS study of Volixibat in PSC is nearing completion, with enrolment expected to finish in the third quarter and top-line data anticipated in second-quarter 2026. Interim data from the VANTAGE study in PBC was presented at EASL, showing durable improvements in pruritus through 28 weeks.

Yahoo Finance
Mar 30th, 2026
Mirum Pharmaceuticals shares 96% up in one year as analysts set fair value at $106.60

Mirum Pharmaceuticals has raised $120 million in a Series C round, though the article primarily focuses on the company's recent share performance rather than a new funding announcement. The stock has delivered a 96% total return over the past year and tripled over five years, currently trading at $88.44. The biopharmaceutical company reported revenue of $521.3 million with a recent net loss of $23.4 million. Analysts value the stock at $106.60 per share, suggesting 17% upside from current levels. Mirum has multiple late-stage pipeline catalysts ahead, including three pivotal study readouts over the next 24 months and initiation of a Phase II Fragile X study. The company's growth prospects depend on maintaining momentum with its Livmarli product and clearing clinical and regulatory hurdles.

Yahoo Finance
Mar 17th, 2026
Mirum completes enrollment in phase III EXPAND study of Livmarli for cholestatic pruritus

Mirum Pharmaceuticals has completed enrollment in its phase III EXPAND study evaluating Livmarli for treating cholestatic pruritus in patients aged six months and above with rare cholestatic liver diseases, including biliary atresia. Top-line data is expected in the fourth quarter of 2026. The double-blind, placebo-controlled study is designed to support a potential label expansion of Livmarli into additional settings. The drug, an orally administered ileal bile acid transporter inhibitor, is currently approved for treating cholestatic pruritus in patients with Alagille syndrome globally and for progressive familial intrahepatic cholestasis in the US and Europe. Livmarli generated $360 million in net product sales in 2025, up 68.8% year over year. Mirum expects worldwide net product sales of approximately $630-$650 million in 2026.

Liver Disease News
Mar 17th, 2026
First results on maralixibat for rare cholestatic itch due by year's end.

First results on maralixibat for rare cholestatic itch due by year's end. Global trial testing oral therapy in rare liver diseases now fully enrolled A global clinical trial testing Mirum Pharmaceuticals' oral therapy maralixibat in people with itching, or pruritus, due to rare cholestatic conditions has finished enrollment, and top-line results are expected before year's end. Mirum announced these updates in a company press release, which noted that the trial's primary goal is "change in pruritus severity" over 20 weeks, or about five months. Maralixibat is already approved in the U.S. and other countries under the name Livmarli for the treatment of itching associated with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), two rare genetic disorders that cause cholestasis, or slowed flow of the digestive fluid bile. This Phase 3 trial, dubbed EXPAND (NCT06553768), is testing the therapy for other rare cholestatic diseases. It was estimated to enroll 90 participants, ages 6 and older, across a dozen countries worldwide. "Completing enrollment in EXPAND marks an important milestone in our efforts to broaden the reach of LIVMARLI to additional patients living with cholestatic pruritus," said Joanne Quan, MD, Mirum's chief medical officer. "Itch due to cholestasis profoundly affects the daily lives of patients and their families." Recommended Reading Normally, bile is made in the liver and shipped to the intestines through a series of tubes called bile ducts. When this flow is blocked or stalled, bile builds up to toxic levels in the liver and leaks into the bloodstream, which can lead to liver damage and cholestasis symptoms such as itching. "For the patients and families living with rare liver diseases, cholestatic pruritus isn't just an itch - it can be relentless, exhausting, and life-altering," said Mercedes Martinez, MD, a professor at Columbia University Vagelos College of Physicians and Surgeons. "Yet for many of these conditions, there are still no approved treatment options for pruritus." That's the case for biliary atresia, a rare disorder affecting infants in which the bile ducts are absent or blocked from birth. Global EXPAND study testing maralixibat for treating itching. Mirum hopes maralixibat can fill a treatment void for these children. Quan said: "We aim to address the unmet medical needs of these patients by leveraging our established IBAT mechanism." Maralixibat is designed to suppress the ileal bile acid transporter (IBAT), a protein that normally helps recycle bile acids - bile's main components - in the intestines back to the liver. Thus, the medication is expected to increase bile excretion in feces, relieving the buildup in the liver and bloodstream and easing itching. After demonstrating that maralixibat is safe and effective at reducing itch in people with Alagille and PFIC, Mirum launched EXPAND to evaluate whether the therapy can also benefit individuals with other rare cholestatic diseases, specifically patients whose condition has failed to respond to other therapies and who have no other treatment options. "The EXPAND study marks an important milestone in exploring whether a targeted therapy like LIVMARLI can offer meaningful relief to patients who urgently need better treatment options," Martinez said. Trial participants, including those with biliary atresia, are being randomly assigned to take either maralixibat (285 micrograms per kg) or a placebo, twice daily, over a period of about five months. The main goal is to assess whether the therapy eases itch severity, as measured with the caregiver-reported ItchRO(Obs) severity score. Secondary goals include changes in blood bile acid levels and other markers of cholestasis. Families affected by biliary atresia and other rare cholestatic conditions understand the relentless burden of itch... The completion of enrollment in EXPAND brings hope that more patients may soon have access to a much-needed treatment option. After the initial placebo-controlled portion of the study, all participants will be treated with maralixibat and monitored for efficacy and safety outcomes. "Families affected by biliary atresia and other rare cholestatic conditions understand the relentless burden of itch," said Jen Lau, co-founder and executive director of BARE (Biliary Atresia Research and Education). "The completion of enrollment in EXPAND brings hope that more patients may soon have access to a much-needed treatment option." Marisa Wexler, MS Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

INACTIVE